Develops, manufactures, and markets medical apparatus, pharmaceuticals, and biomedical CDMO services for healthcare. Now — the numbers.
This is an established company with proven profits.
Average growth of 8% a year over the last 4 years. Every year shown ended in profit.
The gap is $5.6B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 13.2× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 69% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.46 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Against everything we grade, FUJIF lands near the bottom. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FUJIF does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: the revenue breakdown.